ASR-011 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Alomone Labs rabbit anti s1pr1
    MicroPET imaging of <t>S1PR1</t> activity in S aureus -infected mice. (a) Radiosynthesis of S1PR1-specific radiotracer, [ 18 F]TZ4877; (b) representative sagittal microPET images of [ 18 F]TZ4877 in mice. Comparing with sham mice, the tracer uptake was significantly higher in the infected mice, and the increased uptake of the tracer showed S aureus dose dependent; (c) the tracer uptake in the brain was quantified; time-activity curves showed that the tracer uptake in infected mice was significantly higher than mice without infections; (d) the average tracer uptake in the brain from 30 to 50 min of the PET scan showed a dose-dependent manner. Data represent the mean ± SEM, n = 3 for each group.
    Rabbit Anti S1pr1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti s1pr1/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti s1pr1 - by Bioz Stars, 2023-01
    94/100 stars
      Buy from Supplier

    88
    Alomone Labs anti s1p1
    AD2900 shows antagonistic activities against <t> S1P1, </t> 2, 3, 4, and 5
    Anti S1p1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti s1p1/product/Alomone Labs
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti s1p1 - by Bioz Stars, 2023-01
    88/100 stars
      Buy from Supplier

    80
    Alomone Labs anti s1pr1 monoclonal antibody
    OCTA images under influence of pro-and <t>anti-S1PR1</t> agent. (Note that all OCTA images shown above may contain artifact from OCTA itself). A: OCTA imaging of S1PR1 agonist and inverse agonist administration in the deep capillary bed of the retina in the no PC model. Upper row: sham model (no PC and no drug administration). Middle row: sham + SEW model (no PC and SEW administration). Lower row: sham + VPC model (no PC and VPC administration). The appearance of the retinal blood vessels did not change, and no collateral vessel formation occurred in the sham model, sham + SEW administration, and sham + VPC administration groups (images show the deep capillary bed of the retina). B: OCTA imaging of S1PR1 agonist and inverse agonist administration in the deep capillary bed of the retina in the RVO model. Upper row: normal RVO model (no drug administration). Middle row: RVO + SEW (SEW-administration). Lower row: RVO + VPC (VPC-administration). The number of collateral vessels in the RVO + SEW group was significantly greater than in the normal RVO group, and RVO + VPC group (both, p < 0.0001). The number of collateral vessels in the RVO + VPC group tended to be smaller than in the normal RVO group, although this difference was not statistically significant (p = 0.1427). Right schema: the red cross shows the occlusion point. Black radial lines represent the retinal vessels. The blue tortured line represents the newly formed collateral vessels. As illustrated in the right schema, the RVO + SEW group tended to have more collateral vessels than the normal RVO group, and the RVO + VPC group tended to have fewer collateral vessels than the normal RVO group.
    Anti S1pr1 Monoclonal Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 80/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti s1pr1 monoclonal antibody/product/Alomone Labs
    Average 80 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti s1pr1 monoclonal antibody - by Bioz Stars, 2023-01
    80/100 stars
      Buy from Supplier

    Image Search Results


    MicroPET imaging of S1PR1 activity in S aureus -infected mice. (a) Radiosynthesis of S1PR1-specific radiotracer, [ 18 F]TZ4877; (b) representative sagittal microPET images of [ 18 F]TZ4877 in mice. Comparing with sham mice, the tracer uptake was significantly higher in the infected mice, and the increased uptake of the tracer showed S aureus dose dependent; (c) the tracer uptake in the brain was quantified; time-activity curves showed that the tracer uptake in infected mice was significantly higher than mice without infections; (d) the average tracer uptake in the brain from 30 to 50 min of the PET scan showed a dose-dependent manner. Data represent the mean ± SEM, n = 3 for each group.

    Journal: Molecular Imaging

    Article Title: PET Study of Sphingosine-1-phosphate Receptor 1 Expression in Response to S. aureus Infection

    doi: 10.1155/2021/9982020

    Figure Lengend Snippet: MicroPET imaging of S1PR1 activity in S aureus -infected mice. (a) Radiosynthesis of S1PR1-specific radiotracer, [ 18 F]TZ4877; (b) representative sagittal microPET images of [ 18 F]TZ4877 in mice. Comparing with sham mice, the tracer uptake was significantly higher in the infected mice, and the increased uptake of the tracer showed S aureus dose dependent; (c) the tracer uptake in the brain was quantified; time-activity curves showed that the tracer uptake in infected mice was significantly higher than mice without infections; (d) the average tracer uptake in the brain from 30 to 50 min of the PET scan showed a dose-dependent manner. Data represent the mean ± SEM, n = 3 for each group.

    Article Snippet: After washing in PBS, all sections were then incubated with rabbit anti-S1PR1 (Alomone, Israel) antibody overnight at 4°C and then washed and incubated with ImmPRESS HRP Horse anti-rabbit polymer for 1 hour at room temperature and developed with ImmPACT DAB (Vector Laboratories, Burlingame, CA).

    Techniques: Imaging, Activity Assay, Infection

    Biodistribution (%ID/g, mean ± SEM) of  S1PR1-specific  [ 18 F]TZ4877 in Balb/c mice ( n = 4).

    Journal: Molecular Imaging

    Article Title: PET Study of Sphingosine-1-phosphate Receptor 1 Expression in Response to S. aureus Infection

    doi: 10.1155/2021/9982020

    Figure Lengend Snippet: Biodistribution (%ID/g, mean ± SEM) of S1PR1-specific [ 18 F]TZ4877 in Balb/c mice ( n = 4).

    Article Snippet: After washing in PBS, all sections were then incubated with rabbit anti-S1PR1 (Alomone, Israel) antibody overnight at 4°C and then washed and incubated with ImmPRESS HRP Horse anti-rabbit polymer for 1 hour at room temperature and developed with ImmPACT DAB (Vector Laboratories, Burlingame, CA).

    Techniques: Mouse Assay

    Biodistribution of  S1PR1-specific  [ 18 F]TZ4877 in sham, infected, and infected with treatments mice ( n = 4).

    Journal: Molecular Imaging

    Article Title: PET Study of Sphingosine-1-phosphate Receptor 1 Expression in Response to S. aureus Infection

    doi: 10.1155/2021/9982020

    Figure Lengend Snippet: Biodistribution of S1PR1-specific [ 18 F]TZ4877 in sham, infected, and infected with treatments mice ( n = 4).

    Article Snippet: After washing in PBS, all sections were then incubated with rabbit anti-S1PR1 (Alomone, Israel) antibody overnight at 4°C and then washed and incubated with ImmPRESS HRP Horse anti-rabbit polymer for 1 hour at room temperature and developed with ImmPACT DAB (Vector Laboratories, Burlingame, CA).

    Techniques: Infection, Mouse Assay

    MicroPET imaging of S1PR1 activity in S aureus -infected mice. (a) Representative sagittal microPET images of [ 18 F]TZ4877 in the hind limb of mice. The tracer uptake was relatively low in the hind limb muscle with a SUV of ~1.5 in sham mice. Comparing with sham mice, the tracer uptake was significantly higher in the hind limb of infected mice; (b) time-activity curves showed that the tracer uptake in infected mice was significantly higher than sham mice; (c) the average tracer uptake in the hind limb muscle from 30 to 50 min of the PET scan showed a ~39% increase of SUV in infected mice with a P value of 0.0082. Data represent the mean ± SEM, n = 3 for each group.

    Journal: Molecular Imaging

    Article Title: PET Study of Sphingosine-1-phosphate Receptor 1 Expression in Response to S. aureus Infection

    doi: 10.1155/2021/9982020

    Figure Lengend Snippet: MicroPET imaging of S1PR1 activity in S aureus -infected mice. (a) Representative sagittal microPET images of [ 18 F]TZ4877 in the hind limb of mice. The tracer uptake was relatively low in the hind limb muscle with a SUV of ~1.5 in sham mice. Comparing with sham mice, the tracer uptake was significantly higher in the hind limb of infected mice; (b) time-activity curves showed that the tracer uptake in infected mice was significantly higher than sham mice; (c) the average tracer uptake in the hind limb muscle from 30 to 50 min of the PET scan showed a ~39% increase of SUV in infected mice with a P value of 0.0082. Data represent the mean ± SEM, n = 3 for each group.

    Article Snippet: After washing in PBS, all sections were then incubated with rabbit anti-S1PR1 (Alomone, Israel) antibody overnight at 4°C and then washed and incubated with ImmPRESS HRP Horse anti-rabbit polymer for 1 hour at room temperature and developed with ImmPACT DAB (Vector Laboratories, Burlingame, CA).

    Techniques: Imaging, Activity Assay, Infection

    PET measurements of  S1PR1-specific  [ 18 F]TZ4877 in S aureus -infected and sham mice.

    Journal: Molecular Imaging

    Article Title: PET Study of Sphingosine-1-phosphate Receptor 1 Expression in Response to S. aureus Infection

    doi: 10.1155/2021/9982020

    Figure Lengend Snippet: PET measurements of S1PR1-specific [ 18 F]TZ4877 in S aureus -infected and sham mice.

    Article Snippet: After washing in PBS, all sections were then incubated with rabbit anti-S1PR1 (Alomone, Israel) antibody overnight at 4°C and then washed and incubated with ImmPRESS HRP Horse anti-rabbit polymer for 1 hour at room temperature and developed with ImmPACT DAB (Vector Laboratories, Burlingame, CA).

    Techniques: Infection

    Immunohistochemistry analysis of S1PR1 in hind limb muscle of sham and S aureus -infected mice. S1PR1 was significantly upregulated in the muscle of infected mice (red arrow) comparing with sham mice (green arrow), scale bar = 100 μ m.

    Journal: Molecular Imaging

    Article Title: PET Study of Sphingosine-1-phosphate Receptor 1 Expression in Response to S. aureus Infection

    doi: 10.1155/2021/9982020

    Figure Lengend Snippet: Immunohistochemistry analysis of S1PR1 in hind limb muscle of sham and S aureus -infected mice. S1PR1 was significantly upregulated in the muscle of infected mice (red arrow) comparing with sham mice (green arrow), scale bar = 100 μ m.

    Article Snippet: After washing in PBS, all sections were then incubated with rabbit anti-S1PR1 (Alomone, Israel) antibody overnight at 4°C and then washed and incubated with ImmPRESS HRP Horse anti-rabbit polymer for 1 hour at room temperature and developed with ImmPACT DAB (Vector Laboratories, Burlingame, CA).

    Techniques: Immunohistochemistry, Infection

    AD2900 shows antagonistic activities against  S1P1,  2, 3, 4, and 5

    Journal: Oncotarget

    Article Title: The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes

    doi: 10.18632/oncotarget.18626

    Figure Lengend Snippet: AD2900 shows antagonistic activities against S1P1, 2, 3, 4, and 5

    Article Snippet: To analyze S1P1 surface expression on AD2900-treated PBMCs, the following were used: anti-S1P1 (Alomone labs, Israel), anti-EDG-1 (Abcam, UK), Dylight405-conjugated AffiniPure Goat Anti-Rabbit lgG (H + L), and APC-conjugated AffiniPure F(ab')2 Goat Anti-Rabbit lgG(H + L) (Jackson ImmonoResearch, USA).

    Techniques:

    (A, B) The percentages of S1P1-positive PBMCs after the treatment with different concentrations of AD2900, FTY720, or SEW2871 and at different time points were examined by FACS analysis. S1P1 expression was tested in PBMCs after a 30-min treatment with AD2900 at different concentrations (A) or after a 30-min or 60-min treatment with 100 nM AD2900, FTY720, or SEW2871 (B) . (C) The percentage of CCR7-positive PBMCs was tested by FACS analysis after a 30-min treatment with 100 nM AD2900, FTY720, or SEW2871. All the significances are compared to untreated PBMCs. Results summarize the results of at least four independent experiments. Results of Student’s t -test: *(P < 0.05, two-tailed test), ** (P < 0.01, two-tailed test), *** (P < 0.001, two-tailed test), **** (P < 0.0001, two-tailed test).

    Journal: Oncotarget

    Article Title: The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes

    doi: 10.18632/oncotarget.18626

    Figure Lengend Snippet: (A, B) The percentages of S1P1-positive PBMCs after the treatment with different concentrations of AD2900, FTY720, or SEW2871 and at different time points were examined by FACS analysis. S1P1 expression was tested in PBMCs after a 30-min treatment with AD2900 at different concentrations (A) or after a 30-min or 60-min treatment with 100 nM AD2900, FTY720, or SEW2871 (B) . (C) The percentage of CCR7-positive PBMCs was tested by FACS analysis after a 30-min treatment with 100 nM AD2900, FTY720, or SEW2871. All the significances are compared to untreated PBMCs. Results summarize the results of at least four independent experiments. Results of Student’s t -test: *(P < 0.05, two-tailed test), ** (P < 0.01, two-tailed test), *** (P < 0.001, two-tailed test), **** (P < 0.0001, two-tailed test).

    Article Snippet: To analyze S1P1 surface expression on AD2900-treated PBMCs, the following were used: anti-S1P1 (Alomone labs, Israel), anti-EDG-1 (Abcam, UK), Dylight405-conjugated AffiniPure Goat Anti-Rabbit lgG (H + L), and APC-conjugated AffiniPure F(ab')2 Goat Anti-Rabbit lgG(H + L) (Jackson ImmonoResearch, USA).

    Techniques: Expressing, Two Tailed Test

    C57BL/6 mice were orally administered with 1.8, 2.7, and 3.6 mg/l AD2900 or 1.8 mg/l FTY720 for 2 days, as shown in Figure . Leukocytes from blood, spleen, and pLNs were collected and stained with CD3e and S1P1 or CCR7 fluorescent antibodies and then analyzed by FACS analysis. The percentages of S1P1+ CD3e+ T cells from blood (A) , spleen (B) , and pLNs (C) are shown. The percentages of CCR7+ CD3e+ T cells from blood (D) , spleen (E) , and pLNs (F) are shown. All the significances are compared to untreated healthy mice. Results summarize at least three independent experiments. Results of Student’s t -test:*(P < 0.05, two-tailed test), ** (P < 0.01, two-tailed test), *** (P < 0.001, two-tailed test), **** (P < 0.0001, two-tailed test).

    Journal: Oncotarget

    Article Title: The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes

    doi: 10.18632/oncotarget.18626

    Figure Lengend Snippet: C57BL/6 mice were orally administered with 1.8, 2.7, and 3.6 mg/l AD2900 or 1.8 mg/l FTY720 for 2 days, as shown in Figure . Leukocytes from blood, spleen, and pLNs were collected and stained with CD3e and S1P1 or CCR7 fluorescent antibodies and then analyzed by FACS analysis. The percentages of S1P1+ CD3e+ T cells from blood (A) , spleen (B) , and pLNs (C) are shown. The percentages of CCR7+ CD3e+ T cells from blood (D) , spleen (E) , and pLNs (F) are shown. All the significances are compared to untreated healthy mice. Results summarize at least three independent experiments. Results of Student’s t -test:*(P < 0.05, two-tailed test), ** (P < 0.01, two-tailed test), *** (P < 0.001, two-tailed test), **** (P < 0.0001, two-tailed test).

    Article Snippet: To analyze S1P1 surface expression on AD2900-treated PBMCs, the following were used: anti-S1P1 (Alomone labs, Israel), anti-EDG-1 (Abcam, UK), Dylight405-conjugated AffiniPure Goat Anti-Rabbit lgG (H + L), and APC-conjugated AffiniPure F(ab')2 Goat Anti-Rabbit lgG(H + L) (Jackson ImmonoResearch, USA).

    Techniques: Staining, Two Tailed Test

    As an antagonist to S1P receptors 1–5, AD2900 can compete with S1P to bind S1P receptors leading to reduced S1P signaling and enhanced expression of S1P1 on T cells in S1P-rich environments such as the blood and the spleen. This altered expression, together with decreased CCR7 expression, inhibits T-cell entry into the lymph nodes (LNs) from the blood, causing accumulation of T cells in the blood. However, the entry of T cells to the spleen is not affected because it is not S1P dependent. Since Tcm-like cells express CCR7, these cells are attracted to the spleen and accumulate in it; yet, S1P1 elevated expression may have an effect on the S1P-dependent ingression of these cells from the MZ to the white pulp. Tef/em-like cells, which are CCR7 negative, are the primary T-cell subpopulation in the blood after AD2900 treatment. The significant decrease in naive T-cell counts in the circulation and peripheral lymphoid tissues tested may be explained by the inhibition of S1P signaling in the thymus leading to attenuated T-cell egression from the thymus to the circulation. Arrow key: thick = response; dashed = inhibition.

    Journal: Oncotarget

    Article Title: The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes

    doi: 10.18632/oncotarget.18626

    Figure Lengend Snippet: As an antagonist to S1P receptors 1–5, AD2900 can compete with S1P to bind S1P receptors leading to reduced S1P signaling and enhanced expression of S1P1 on T cells in S1P-rich environments such as the blood and the spleen. This altered expression, together with decreased CCR7 expression, inhibits T-cell entry into the lymph nodes (LNs) from the blood, causing accumulation of T cells in the blood. However, the entry of T cells to the spleen is not affected because it is not S1P dependent. Since Tcm-like cells express CCR7, these cells are attracted to the spleen and accumulate in it; yet, S1P1 elevated expression may have an effect on the S1P-dependent ingression of these cells from the MZ to the white pulp. Tef/em-like cells, which are CCR7 negative, are the primary T-cell subpopulation in the blood after AD2900 treatment. The significant decrease in naive T-cell counts in the circulation and peripheral lymphoid tissues tested may be explained by the inhibition of S1P signaling in the thymus leading to attenuated T-cell egression from the thymus to the circulation. Arrow key: thick = response; dashed = inhibition.

    Article Snippet: To analyze S1P1 surface expression on AD2900-treated PBMCs, the following were used: anti-S1P1 (Alomone labs, Israel), anti-EDG-1 (Abcam, UK), Dylight405-conjugated AffiniPure Goat Anti-Rabbit lgG (H + L), and APC-conjugated AffiniPure F(ab')2 Goat Anti-Rabbit lgG(H + L) (Jackson ImmonoResearch, USA).

    Techniques: Expressing, Inhibition

    OCTA images under influence of pro-and anti-S1PR1 agent. (Note that all OCTA images shown above may contain artifact from OCTA itself). A: OCTA imaging of S1PR1 agonist and inverse agonist administration in the deep capillary bed of the retina in the no PC model. Upper row: sham model (no PC and no drug administration). Middle row: sham + SEW model (no PC and SEW administration). Lower row: sham + VPC model (no PC and VPC administration). The appearance of the retinal blood vessels did not change, and no collateral vessel formation occurred in the sham model, sham + SEW administration, and sham + VPC administration groups (images show the deep capillary bed of the retina). B: OCTA imaging of S1PR1 agonist and inverse agonist administration in the deep capillary bed of the retina in the RVO model. Upper row: normal RVO model (no drug administration). Middle row: RVO + SEW (SEW-administration). Lower row: RVO + VPC (VPC-administration). The number of collateral vessels in the RVO + SEW group was significantly greater than in the normal RVO group, and RVO + VPC group (both, p < 0.0001). The number of collateral vessels in the RVO + VPC group tended to be smaller than in the normal RVO group, although this difference was not statistically significant (p = 0.1427). Right schema: the red cross shows the occlusion point. Black radial lines represent the retinal vessels. The blue tortured line represents the newly formed collateral vessels. As illustrated in the right schema, the RVO + SEW group tended to have more collateral vessels than the normal RVO group, and the RVO + VPC group tended to have fewer collateral vessels than the normal RVO group.

    Journal: Heliyon

    Article Title: Time course of collateral vessel formation after retinal vein occlusion visualized by OCTA and elucidation of factors in their formation

    doi: 10.1016/j.heliyon.2021.e05902

    Figure Lengend Snippet: OCTA images under influence of pro-and anti-S1PR1 agent. (Note that all OCTA images shown above may contain artifact from OCTA itself). A: OCTA imaging of S1PR1 agonist and inverse agonist administration in the deep capillary bed of the retina in the no PC model. Upper row: sham model (no PC and no drug administration). Middle row: sham + SEW model (no PC and SEW administration). Lower row: sham + VPC model (no PC and VPC administration). The appearance of the retinal blood vessels did not change, and no collateral vessel formation occurred in the sham model, sham + SEW administration, and sham + VPC administration groups (images show the deep capillary bed of the retina). B: OCTA imaging of S1PR1 agonist and inverse agonist administration in the deep capillary bed of the retina in the RVO model. Upper row: normal RVO model (no drug administration). Middle row: RVO + SEW (SEW-administration). Lower row: RVO + VPC (VPC-administration). The number of collateral vessels in the RVO + SEW group was significantly greater than in the normal RVO group, and RVO + VPC group (both, p < 0.0001). The number of collateral vessels in the RVO + VPC group tended to be smaller than in the normal RVO group, although this difference was not statistically significant (p = 0.1427). Right schema: the red cross shows the occlusion point. Black radial lines represent the retinal vessels. The blue tortured line represents the newly formed collateral vessels. As illustrated in the right schema, the RVO + SEW group tended to have more collateral vessels than the normal RVO group, and the RVO + VPC group tended to have fewer collateral vessels than the normal RVO group.

    Article Snippet: The following antibodies were used for wholemount immunolabeling of the retina: anti-CD31 monoclonal antibody (rat anti-mouse CD31, 1:500; BD Biosciences Pharmingen, San Diego, CA, USA) was used to detect blood vessels with Alexa Fluor-568 secondary antibody (1:400); anti-S1PR1 monoclonal antibody (rabbit anti-mouse, rat S1PR1, 1:200; Almone Labs, Jerusalem, MA, USA) was used to detect S1PR1 with Alexa Fluor-488 secondary antibody (1:400).

    Techniques: Imaging

    A: Average number of collateral vessels per eye. The average number of collateral vessels per eye was 1.66 in the normal RVO group, 4.11 in the RVO + SEW group, and 0.71 in the RVO + VPC group. The number of collateral vessels differed among the normal RVO group, RVO + SEW group, and RVO + VPC group (p < 0.0001). In addition, the number of collateral vessels in the RVO + SEW group was also significantly higher than in the normal RVO group and RVO + VPC group (p < 0.0001 for both groups). The number of collateral vessels in the RVO + VPC group tended to be smaller than in the normal RVO group, although the difference was not statistically significant (p = 0.1427). B: RT-PCR for S1PR1 expression in the whole retina. Differences in the mean levels of S1PR1 expression were observed between the control group (no laser irradiation and no drug administration), and at time points 6 h, 12 h, 24 h, and 3 days after laser irradiation (p < 0.0001). The levels of S1PR1 expression 6 h (p < 0.0001) and 12 h (p = 0.0023) after laser irradiation were significantly higher than the sham, and these levels then gradually decreased and did not increase thereafter. When comparing S1PR1 expression levels between 6 h and 12 h post-laser irradiation, the expression at 6 h was significantly greater than at 12 h (p < 0.0001). The expression of S1PR1 mRNA peaked by about 6 h after blood vessel occlusion, and was significantly greater than control levels.

    Journal: Heliyon

    Article Title: Time course of collateral vessel formation after retinal vein occlusion visualized by OCTA and elucidation of factors in their formation

    doi: 10.1016/j.heliyon.2021.e05902

    Figure Lengend Snippet: A: Average number of collateral vessels per eye. The average number of collateral vessels per eye was 1.66 in the normal RVO group, 4.11 in the RVO + SEW group, and 0.71 in the RVO + VPC group. The number of collateral vessels differed among the normal RVO group, RVO + SEW group, and RVO + VPC group (p < 0.0001). In addition, the number of collateral vessels in the RVO + SEW group was also significantly higher than in the normal RVO group and RVO + VPC group (p < 0.0001 for both groups). The number of collateral vessels in the RVO + VPC group tended to be smaller than in the normal RVO group, although the difference was not statistically significant (p = 0.1427). B: RT-PCR for S1PR1 expression in the whole retina. Differences in the mean levels of S1PR1 expression were observed between the control group (no laser irradiation and no drug administration), and at time points 6 h, 12 h, 24 h, and 3 days after laser irradiation (p < 0.0001). The levels of S1PR1 expression 6 h (p < 0.0001) and 12 h (p = 0.0023) after laser irradiation were significantly higher than the sham, and these levels then gradually decreased and did not increase thereafter. When comparing S1PR1 expression levels between 6 h and 12 h post-laser irradiation, the expression at 6 h was significantly greater than at 12 h (p < 0.0001). The expression of S1PR1 mRNA peaked by about 6 h after blood vessel occlusion, and was significantly greater than control levels.

    Article Snippet: The following antibodies were used for wholemount immunolabeling of the retina: anti-CD31 monoclonal antibody (rat anti-mouse CD31, 1:500; BD Biosciences Pharmingen, San Diego, CA, USA) was used to detect blood vessels with Alexa Fluor-568 secondary antibody (1:400); anti-S1PR1 monoclonal antibody (rabbit anti-mouse, rat S1PR1, 1:200; Almone Labs, Jerusalem, MA, USA) was used to detect S1PR1 with Alexa Fluor-488 secondary antibody (1:400).

    Techniques: Reverse Transcription Polymerase Chain Reaction, Expressing, Irradiation

    Immunofluorescence imaging of retinal flat mounts. a: Immunohistochemical staining for CD31 at day 1 post-PC. b: Immunohistochemical staining for S1PR1 at day 1 post-PC. c: Immunohistochemical staining for CD31 at day 3 post-PC. d: Immunohistochemical staining for S1PR1 at day 3 post-PC. White oval: occluded vein. On day 1 post-PC, S1PR1 staining occurred along the laser-occluded blood vessel, but was not present along other blood vessels. There was no prominent staining for S1PR1 along the occluded blood vessels after the first day post-PC.

    Journal: Heliyon

    Article Title: Time course of collateral vessel formation after retinal vein occlusion visualized by OCTA and elucidation of factors in their formation

    doi: 10.1016/j.heliyon.2021.e05902

    Figure Lengend Snippet: Immunofluorescence imaging of retinal flat mounts. a: Immunohistochemical staining for CD31 at day 1 post-PC. b: Immunohistochemical staining for S1PR1 at day 1 post-PC. c: Immunohistochemical staining for CD31 at day 3 post-PC. d: Immunohistochemical staining for S1PR1 at day 3 post-PC. White oval: occluded vein. On day 1 post-PC, S1PR1 staining occurred along the laser-occluded blood vessel, but was not present along other blood vessels. There was no prominent staining for S1PR1 along the occluded blood vessels after the first day post-PC.

    Article Snippet: The following antibodies were used for wholemount immunolabeling of the retina: anti-CD31 monoclonal antibody (rat anti-mouse CD31, 1:500; BD Biosciences Pharmingen, San Diego, CA, USA) was used to detect blood vessels with Alexa Fluor-568 secondary antibody (1:400); anti-S1PR1 monoclonal antibody (rabbit anti-mouse, rat S1PR1, 1:200; Almone Labs, Jerusalem, MA, USA) was used to detect S1PR1 with Alexa Fluor-488 secondary antibody (1:400).

    Techniques: Immunofluorescence, Imaging, Immunohistochemical staining, Staining